Skip to main content

Invega Hafyera

Generic name: paliperidone palmitate
Dosage form: extended-release injectable suspension
Drug class: Atypical antipsychotics

Medically reviewed by Judith Stewart, BPharm. Last updated on Sep 2, 2021.

What is Invega Hafyera?

Invega Hafyera is a prescription medicine given by injection by a healthcare provider 1 time every 6 months and used for the treatment of schizophrenia in adults who have been adequately treated with either:

  • A 1 time each month paliperidone palmitate extended-release injectable suspension for at least 4 months.
  • A 1 time every 3 months paliperidone palmitate extended-release injectable suspension for at least 3 months.

It is not known if this medicine is safe and effective in children under 18 years of age.

Important information

Invega Hafyera may cause serious side effects, including:

  • Increased risk of death in elderly people with dementia-related psychosis. Invega Hafyera increases the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Invega Hafyera is not for the treatment of people with dementia-related psychosis.

Who should not receive Invega Hafyera?

You should not receive Invega Hafyera if you are allergic to paliperidone palmitate, risperidone, or any of the ingredients. See the end of this page for a complete list of ingredients.

Before receiving Invega Hafyera

Before you start treatment, tell your healthcare provider about all your medical conditions, including if you:

  • have had Neuroleptic Malignant Syndrome (NMS)
  • have or have had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
  • have or have had low levels of potassium or magnesium in your blood
  • have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
  • have or have had kidney or liver problems
  • have diabetes or have a family history of diabetes
  • have Parkinson’s disease or a type of dementia called Lewy Body Dementia
  • have had a low white blood cell count
  • have had problems with dizziness or fainting or are being treated for high blood pressure
  • have or have had seizures or epilepsy
  • are pregnant or plan to become pregnant. It is not known if Invega Hafyera will harm your unborn baby.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment.
    • If you become pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and research-programs/pregnancyregistry/.
    • Babies born to mothers who receive Invega Hafyera during their third trimester of pregnancy may develop agitation, low muscle tone (floppy baby syndrome) tremors, excessive sleepiness, breathing problems, and feeding problems. Tell your healthcare provider right away if your baby develops any of these symptoms.
  • are breastfeeding or plan to breastfeed. Invega Hafyera can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

What other drugs will affect Invega Hafyera?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Invega Hafyera and other medicines may affect each other causing possible serious side effects. Invega Hafyera may affect the way other medicines work, and other medicines may affect how Invega Hafyera works.
Your healthcare provider can tell you if it is safe to receive Invega Hafyera with your other medicines. Do not start or stop any medicines during treatment without talking to your healthcare provider first.

Know the medicines you take. Keep a list of them to show to your healthcare provider or pharmacist when you get a new medicine.

How will I receive Invega Hafyera?

  • Follow your treatment schedule exactly as your healthcare provider tells you to.
  • Your healthcare provider will tell you how much Invega Hafyera you will receive and when you will receive it.
  • Invega Hafyera is given as an injection by your healthcare provider into the muscle (intramuscularly) of your buttocks, 1 time every 6 months.

Dosing information

Usual Adult Dose of Invega Hafyera for Schizophrenia:

- Administer Invega Hafyera by gluteal injection once every 6 months
- Patients should be adequately treated with: 

    • a once-a-month paliperidone palmitate extended-release injectable suspension (e.g., Invega Sustenna) for at least four months or
    • an every-three-month paliperidone palmitate extended-release injectable suspension (e.g., Invega Trinza) for at least one three-month cycle.

Doses for Adults Adequately Treated with once-a-month paliperidone palmitate extended-release injectable suspension (PP1M)

If the Last Dose of PP1M is: Initiate Invega Hafyera at the Following Dose:
156 mg 1,092 mg
234 mg 1,560 mg

Doses for Adults Adequately Treated with every-three-month paliperidone palmitate injectable suspension (PP3M)

If the Last Dose of PP3M is: Initiate Invega Hafyera at the Following Dose:
546 mg 1,092 mg
819 mg 1,560 mg

What should I avoid while receiving Invega Hafyera?

  • Do not drive, operate heavy machinery, or do other dangerous activities until you know how Invega Hafyera affects you. Invega Hafyera may affect your judgment, thinking, or motor skills.
  • Avoid getting too hot or dehydrated.
  • Do not exercise too much.
  • In hot weather, stay inside in a cool place if possible.
  • Stay out of the sun.
  • Do not wear too much clothing or heavy clothing.
  • Drink plenty of water.

Invega Hafyera side effects

Invega Hafyera may cause serious side effects, including:

  • See Important information.
  • Cerebrovascular problems (including stroke) in elderly people with dementia-related psychosis that can lead to death.
  • Neuroleptic Malignant Syndrome (NMS), a serious condition that can lead to death. Call your healthcare provider or go to your nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS:
    • high fever
    • confusion
    • changes in your breathing, pulse, heart rate, and blood pressure
    • stiff muscles
    • sweating
  • Problems with your heartbeat. These heart problems can cause death. Call your healthcare provider right away if you have any of these symptoms:
    • passing out or feeling like you will pass out
    • dizziness
    • feeling as if your heart is pounding or missing beats
  • Uncontrolled body movements (tardive dyskinesia). Invega Hafyera may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop treatment. Tardive dyskinesia may also start after you stop treatment.
  • Problems with your metabolism such as
    • high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who receive Invega Hafyera. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before you start and regularly during treatment.
      Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment:
      • feel very thirsty
      • need to urinate more than usual
      • feel very hungry
      • feel weak or tired
      • feel sick to your stomach
      • feel confused, or your breath smells fruity
    • increased fat levels (cholesterol and triglycerides) in your blood. Your healthcare provider should check the fat levels in your blood before you start and regularly during treatment.
    • weight gain. You and your healthcare provider should check your weight before you start and often during treatment.
  • Decreased blood pressure (orthostatic hypotension) and fainting. You may feel lightheaded or faint when you rise too quickly from a sitting or lying position, especially early in treatment or when the dose is changed.
  • Falls. Invega Hafyera may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.
  • Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment.
  • Increased prolactin levels in your blood (hyperprolactinemia). Invega Hafyera may cause a rise in the blood levels of a hormone called prolactin (hyperprolactinemia) that may cause side effects including missed menstrual periods, a reversible reduction in fertility in females who are able to become pregnant, leakage of milk from the breasts, development of breasts in men, or problems with erection.
  • Invega Hafyera can make you sleepy or dizzy, and can slow your thinking and motor skills. Do not drive, operate heavy machinery, or do other dangerous activities until you know how Invega Hafyera affects you.
  • Seizures (convulsions).
  • Difficulty swallowing that can cause food or liquid to get into your lungs.
  • Prolonged or painful erection lasting more than 4 hours (priapism). Call your healthcare provider or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.
  • Problems controlling your body temperature so that you feel too warm. See, What should I avoid while receiving Invega Hafyera?

The most common side effects include:

  • upper respiratory tract infections
  • weight gain
  • feeling restlessness or difficulty sitting still
  • tremors
  • shuffling walk
  • injection site reactions
  • headache
  • slow movements
  • stiffness

These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800 FDA-1088.

General information about Invega Hafyera.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information that is written for health professionals.

What are the ingredients in Invega Hafyera?

Active ingredient: paliperidone palmitate
Inactive ingredients: polysorbate 20, polyethylene glycol 4000, citric acid monohydrate, sodium dihydrogen phosphate monohydrate, sodium hydroxide, and water for injection

Popular FAQ

You should avoid the use of alcohol while being treated with Invega Sustenna (paliperidone palmitate). Combining alcohol with Invega Sustenna can increase side effects like dizziness, drowsiness, and trouble concentrating. This may also affect your ability to make decisions, think clearly, or react quickly.  Continue reading

The difference between Invega Sustenna, Invega Trinza, and Invega Hayfera is the length of time they last in the body. Invega Sustenna lasts for 1 month, Invega Trinza lasts for 3 months, and Invega Hayfera lasts for 6 months and only needs to be given twice a year. Before transitioning to Invega Hayfera, patients must be adequately treated with Invega Sustenna for at least 4 months, or Invega Trinza for at least one 3-month injection cycle. Continue reading

Before people transition to Invega Trinza, they need to have been administered Invega Sustenna for at least 4 months and tolerated it well. For a seamless transition, it is recommended that the last two doses of Invega Sustenna are the same dosage strength before starting Invega Trinza. Start Invega Trinza up to 7 days before, on, or 7 days after the day the next 1-month Invega Sustenna dose was due. Choose a starting dose of Invega Trinza that is 3.5-fold higher than the last Invega Sustenna dose. Continue reading

Before transitioning to Invega Hayfera, a person must have been administered Invega Sustenna for at least 4 months or Invega Trinza for at least one three-month cycle and tolerated either of them well. Continue reading

Invega Trinza (paliperidone palmitate) is a long-acting injection given into the muscle of your upper arm (deltoid muscle) or buttock (gluteal muscle). It is given once every 3 months for the treatment of schizophrenia. Your healthcare provider will give you this injection each time. Continue reading

Invega Sustenna is administered by a healthcare professional into either the deltoid muscle of the arm or the gluteal muscle of the buttocks once a month following an initial loading dose period. Invega Sustenna is usually started with a dose of 234mg given IM, followed by 156mg IM one week later. Thereafter, monthly injections of 39mg to 234mg IM are given, depending on the condition being treated, individual dosage requirements, and how well the person tolerates Invega Sustenna. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.